SynthesisOncotarget2016
The prognostic value of long non coding RNAs in non small cell lung cancer: A meta-analysis.
Synthesis in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Value of Dysregulated LncRNAs on Clinicopathology and Survival in Non-Small-Cell LungFrontiers in genetics · 2022Pooled it
- The prognostic significance of long noncoding RNAs in bladder cancer: A meta-analysis.PloS one · 2018Pooled it
- The Good, the Bad, or Both? Unveiling the Molecular Functions of LINC01133 in Tumors.Non-coding RNA · 2025Article
- Comprehensive review of LncRNA-mediated therapeutic resistance in non-small cell lung cancer.Cancer cell international · 2024Review
- Characterization of an endoplasmic reticulum stress-associated lncRNA prognostic signature and the tumor-suppressive role of RP11-295G20.2 knockdown in lung adenocarcinoma.Scientific reports · 2024Article
- An Overview of the Immune Modulatory Properties of Long Non-Coding RNAs and Their Potential Use as Therapeutic Targets in Cancer.Non-coding RNA · 2023Review
- Prognostic value of Beclin 1, EGFR and ALK in non-squamous non-small cell lung cancer.Discover oncology · 2022Article
- Molecular Pathology of Lung Cancer.Cold Spring Harbor perspectives in medicine · 2022Review
- MiR-582-3p participates in the regulation of biological behaviors of A549 cells by ambient PMEnvironmental science and pollution research international · 2022Article
- The roles of long non-coding RNAs in lung cancer.Journal of Cancer · 2022Review
- Microarray analysis of differentially expressed long non-coding RNAs in daidzein-treated lung cancer cells.Oncology letters · 2021Article
- A narrative review of prognosis prediction models for non-small cell lung cancer: what kind of predictors should be selected and how to improve models?Annals of translational medicine · 2021Review
- AFAP1-AS1: a rising star among oncogenic long non-coding RNAs.Science China. Life sciences · 2021Review
- A Review on the Role of AFAP1-AS1 in the Pathoetiology of Cancer.Frontiers in oncology · 2021Review
- lncRNA AFAP1-AS1 promotes triple negative breast cancer cell proliferation and invasion via targeting miR-145 to regulate MTH1 expression.Scientific reports · 2020Article
- Article
- Review
- Roles of Oncogenic Long Non-coding RNAs in Cancer Development.Genomics & informatics · 2018Article
- Snail mediates repression of the Dlk1-Dio3 locus in lung tumor-infiltrating immune cells.Oncotarget · 2018Article
- Long non-coding RNA linc01433 promotes migration and invasion in non-small cell lung cancer.Thoracic cancer · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundReports have demonstrated the prognostic function of long non-coding RNAS (lncRNAS) in patients with cancer. However, their prognostic functions in non small cell lung cancer (NSCLC) remain controversial. We therefore performed a meta-analysis on six lncRNAs (PVT1, AFAP1-AS1, LINC01133, ANRIL, MEG3 and UCA1) to clarify their prognostic roles in NSCLC.
resultsThirty-six studies involving 6267 patients with NSCLC and 34 lncRNAs were included. Of the listed lncRNAs, 20 were shown to negatively affect patients' overall survival while the high expression of 13 lncRNAs indicated better survival outcomes. MATERIALS AND
methodsThe log-rank p value and Kaplan-Meier survival curves of survival outcomes were extracted for hazard ratio (HR) calculation. Survival outcomes were measured by overall survival (OS) and event free survival (EFS) which were then analyzed by calculating pooled hazard ratios. The heterogeneity was detected by Q statistic and I-squared statistic.
conclusionsThe abnormal expression of lncRNAs may significantly affect NSCLC patients' survival and may serve as a novel predictive factor for prognosis of NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.